Author(s): Campbell JR; Russell WA; Wagner CE; Manuel DG; Anipindi V; Baral P; Evans TG; Hankins CA; Sander B;

The Government of Canada, through the COVID-19 Immunity Task Force (CITF), supported over 100 serosurveillance studies during the COVID-19 pandemic, building and strengthening the technical infrastructure necessary for a national serosurveillance network. The value of such a network extends beyon ...

Article GUID: 40588636

Author(s): Silva MCJD; Pinto AMV; Balthar MA; Correa ABA; Bhattacharyya D; Simas ABC; Kuca K; Forgione P; França TCC; Cavalcante SFA; Kitagawa DAS;

Given the recent deployment of nerve agents as a method of warfare and in targeted assassinations, the development of robust, broad-spectrum medical countermeasures is essential. Our research group has synthesized isatin-pyridine oxime hybrids that have previously demonstrated the ability to resc ...

Article GUID: 40516590

Author(s): Sánchez-Carro Y; Moukarzel M; Friedrich MG; Gouin JP; Luu JM;

Objective: Beyond objective socioeconomic status (SES) indicators, subjective social status (SSS), an individual's subjective perception of their social standing relative to others, has been independently linked to cardiovascular disease (CVD) morbidity and mortality. Some studies also report sex differences in the association between SSS and CVD. Thi ...

Article GUID: 40471966

Author(s): Eskandari K; Bélanger SM; Lachance V; Kourrich S;

Neurodegenerative disorders, such as Alzheimer's, Parkinson's, and Huntington's disease, due to their multifaced and complicated nature, remain uncurable and impose substantial financial and human burdens on society. Therefore, developing new innovative therapeutic strategies is vital. In this context, drug repurposing has emerged as a promisi ...

Article GUID: 40430519

Author(s): Sanami S; Intzandt B; Huck J; Villeneuve S; Iturria-Medina Y; Gauthier CJ; Prevent-Ad Research Group None;

Alzheimer's disease (AD) is a complex disease that involves complex interactions between protein biomarkers such as amyloid beta (Aß) and tau, neurodegeneration, cerebrovascular health and inflammation. However, how these factors interact, especially in the early phases of disease development ...

Article GUID: 40347524

Author(s): Pellerin S; Houzé B; Bedetti C; Phillips N; Brambati SM;

BackgroundMild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD) for many individuals, is accompanied by widespread connected speech (CS) changes (e.g., shorter CS samples, mention of fewer semantic content units, lower syntactic complexity). Nevertheless, findings on CS in MCI are heterogeneous. This heterogeneity, combined wi ...

Article GUID: 40232260

Author(s): Sim M; Gebre AK; Dalla Via J; Reid S; Jozani MJ; Kimelman D; Monchka BA; Gilani SZ; Ilyas Z; Smith C; Suter D; Schousboe JT; Lewis JR; Leslie WD;

Abdominal aortic calcification (AAC), a subclinical measure of cardiovascular disease (CVD) that can be assessed on vertebral fracture assessment (VFA) images during osteoporosis screening, is reported to be a falls risk factor. A limitation to incorporating AAC clinically is that its scoring req ...

Article GUID: 40080298

Author(s): Muffels IJJ; Waterham HR; D' Alessandro G; Zagnoli-Vieira G; Sacher M; Lefeber DJ; Van der Vinne C; Roifman CM; Gassen KLI; Rehmann H; Van Haaften-Visser DY; Nieuwenhuis ESS; Jackson SP; Fuchs SA; Wijk F; van Hasselt P;

Background: Deciphering variants of uncertain significance (VUS) represents a major diagnostic challenge, partially due to the lack of easy-to-use and versatile cellular readouts that aid the interpretation of pathogenicity and pathophysiology. To address this challenge, we propose a high-through ...

Article GUID: 39920830

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139

Author(s): Páez A; Gillman SO; Dogaheh SB; Carnes A; Dakterzada F; Barbé F; Dang-Vu TT; Ripoll GP;

Introduction: Changes in sleep physiology can predate cognitive symptoms by decades in persons with Alzheimer's disease (AD), but it remains unclear which sleep characteristics predict cognitive and neurodegenerative changes after AD onset. Methods: Using data from a prospective cohort of mild to moderate AD (n = 60), we analyzed non-rapid eye moveme ...

Article GUID: 39878233

Author(s): Meade O; Aehlig L; O' Brien M; Lawless A; McSharry J; Dragomir A; Hart JK; Keyworth C; Lavoie KL; Byrne M;

Objectives: Behaviour change interventions offered opportunistically by healthcare professionals can support patient health behaviour change. The Making Every Contact Count (MECC) programme in Ireland is a national programme to support healthcare professionals to use brief behavioural interventio ...

Article GUID: 39815763